



Northera® (droxidopa) – First-time generic

- On February 19, 2021, Aurobindo, Ajanta, Sun, Zydus, Ascend/Alkem, [Camber/Annora](#), and Novadoz/MSN launched [AB-rated](#) versions of Lundbeck's [Northera \(droxidopa\)](#) capsules.
 - Additionally, [Hikma](#), [Lupin](#), [Sciegen](#), [Tasman](#) and [Teva](#) received FDA approval of AB-rated generic versions of Northera. Launch plans of these generics are pending.
- Northera is approved for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.
- Northera carries a boxed warning for supine hypotension.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.